PARIS--(BUSINESS WIRE)--AB Science SA (Paris:AB)(NYSE-Euronext, FR0010557264, AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of a wide-ranging review article entitled ‘Masitinib – a targeted therapy with applications in veterinary oncology and inflammatory diseases’ in the peer-reviewed journal CAB Reviews and on the veterinary continuing education website VetMed Resources.
